Janux Therapeutics (JANX) Return on Sales: 2021-2025
Historic Return on Sales for Janux Therapeutics (JANX) over the last 3 years, with Sep 2025 value amounting to -4.95%.
- Janux Therapeutics' Return on Sales fell 31.00% to -4.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.95%, marking a year-over-year decrease of 31.00%. This contributed to the annual value of -6.52% for FY2024, which is 70.00% up from last year.
- Latest data reveals that Janux Therapeutics reported Return on Sales of -4.95% as of Q3 2025, which was down 6.68% from -4.64% recorded in Q3 2024.
- Janux Therapeutics' Return on Sales' 5-year high stood at -2.91% during Q2 2024, with a 5-year trough of -10.87% in Q3 2021.
- Moreover, its 3-year median value for Return on Sales was -7.30% (2023), whereas its average is -6.36%.
- In the last 5 years, Janux Therapeutics' Return on Sales plummeted by 63bps in 2023 and then skyrocketed by 581bps in 2024.
- Quarterly analysis of 5 years shows Janux Therapeutics' Return on Sales stood at -8.98% in 2021, then spiked by 166bps to -7.32% in 2022, then increased by 11bps to -7.21% in 2023, then spiked by 275bps to -4.64% in 2024, then tumbled by 31bps to -4.95% in 2025.
- Its last three reported values are -4.95% in Q3 2025, -4.64% for Q3 2024, and -2.91% during Q2 2024.